Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adrenocortical carcinoma.

Steven E Rodgers1, Douglas B Evans, Jeffrey E Lee

  • 1Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA.

Surgical Oncology Clinics of North America
|August 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Modern Presentation, Etiology, and Rate of Occurrence of Cushing Syndrome Differs when Compared to Prior Population-Based Studies.

AACE endocrinology and diabetes·2026
Same author

AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma.

JAMA surgery·2026
Same author

Development and implementation of an innovative mentoring committee for early-career faculty members.

Surgery·2026
Same author

Adrenalectomy patients with mixed primary aldosteronism and hypercortisolism: An analysis of outcomes following surgery at a single institution.

Surgery·2025
Same author

Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.

Cancer research·2025
Same author

The impact of adrenalectomy on metabolic outcomes of patients with mild autonomous cortisol secretion defined by low-dose dexamethasone suppression testing.

Surgery·2025
Same journal

Small Incisions, Big Impact-Robotic Surgery Is Revolutionizing Cancer Care.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Cancer.

Surgical oncology clinics of North America·2026
Same journal

TeleSurgery: The Present and the Future for Minimally Invasive and Robotic Surgery.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Rectal Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive/Robotic Surgery for Colon Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery in Liver Transplantation.

Surgical oncology clinics of North America·2026
See all related articles

Adrenocortical carcinoma (ACC) is aggressive, often recurring despite treatment. Combining mitotane with chemotherapy may improve survival for patients with recurrent or metastatic ACC.

Area of Science:

  • Endocrinology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a poor prognosis.
  • Early diagnosis and complete surgical resection are crucial for improving patient survival.
  • Despite optimal treatment, recurrence is common due to tumor biology, resection challenges, and limited systemic therapies.

Purpose of the Study:

  • To review the current treatment landscape for adrenocortical carcinoma.
  • To highlight the role of mitotane in managing high-risk, recurrent, or metastatic ACC.
  • To explore the potential benefits of combining mitotane with chemotherapy.

Main Methods:

  • Literature review of studies on adrenocortical carcinoma treatment.
  • Analysis of data regarding mitotane efficacy and safety.

Related Experiment Videos

  • Evaluation of combination therapy approaches, including chemotherapy.

    • Main Results:

    • Mitotane remains a primary treatment for high-risk ACC, particularly in recurrent or metastatic settings.
    • Most ACC patients experience recurrence despite initial treatment.
    • Emerging evidence suggests combination therapy with mitotane and chemotherapy may enhance survival.

    Conclusions:

    • Adrenocortical carcinoma presents significant treatment challenges.
    • Mitotane is a critical component in managing advanced ACC.
    • Combination strategies involving mitotane show promise for improving outcomes in ACC patients.